AXGN Axogen Inc.

$AXGN $AXGN BEAR CASE: Stock surges 20%+ despite gross margins falling from 76.6% to 74.8% and GAAP EPS of just $0.04. Operating income declined despite 26% revenue growth. At nearly $50, I would CASH OUT

$AXGN at 6pm today we'll see the short interest data as of October 15. If that shows a larger short position and we have a clean ER anc CC, this could explode. Shorts are betting on friction and drag on margin with the integration of the BioCircuit acquisition. If we see solid numbers and guidance remains strong, look out above. Most shares are locked up (at least on an intraday basis) with institutions. Expect volatility to increase toward Weds.

$AXGN in September of last year I loaded up wife's IRA with AXGN and never touched it. I'm getting some, bois!!

$AXGN From my latest buying spree in my SDBA as communicated. Hope they all came from short sales. Congrats to the longs that stuck it out. Was a tough drawdown for sure.

$AXGN It's a beautiful day in the neighborhood! Looks to be a triple beat: Revenue was $75.8 million, an increase of 26.2% ($60.1 million for QTR3 2025). Net income was $2.3 million, or $0.04 per share, ($0.7 million, or $0.01 per share for QTR3 2025) Adjusted net income was $13.1 million, or $0.21 per share ($6.1 million, or $0.12 per share for QTR3 2025). Full year revenue guidance raised to at least 29% growth or $290 million.

$AXGN is on fire, ripping about 31% today and around 34% over five sessions after a solid Q3 beat and updated guidance The BioCircuit acquisition news adds to the hype but watch for potential pullbacks with this volatility Options flow is all about calls lately, 100% calls over the last five sessions We've seen about 1,837 contracts and around $881K in premium focused on slightly in-the-money 11/20 strikes Check out that 355-contract pre-earnings $35 sweep at about 103% IV on InsiderFinance Traders are going for higher delta near-term calls, betting on continued momentum rather than cheap lottos Implied volatility has dropped from about 103% to the low-mid 40s

$AXGN The strongest bull response to an ER ever for this name I believe. Probably going to turn 20% float by EOD.. and bears think they're going to talk it down with a couple of cherrypicked data points that mean nothing. 😂

$AXGN brokers buying and selling to themselves for now will be back to $40 soon bearish at this price

$AXGN Q3 revenue grew 26%, yet GAAP net margin was only 3%, and gross margin contracted 180 basis points

$AXGN GAAP profit was just $2.3M—a thin 3% net margin. Gross margin fell 180 bps to 74.8%. At 7.6x annual sales pre-rally, valuation looks stretched. Not a $46 stock 😆

Mizuho⬆️ $AXGN's PT to $65, reiterated Outperform and Provided Key Post-Call Updates from its Call with Management. [IART BAX SYK MDT ABT BSX AMIX] Mizuho said: 1) base organic growth of +27% being driven by inflection in Breast along with continued "double-digit" growth in combined Extremities + OMF channels, 2) Breast Resensation penetration reached +11% of the estimated 140-150k annual reconstruction surgeries exiting September, 3) plan in Breast is to eventually reach top 2k Plastic Surgeon sites focused on tissue sparing surgeries (up from 500 live sites today), 4) co will double Breast salesforce from the current 31 to realize full growth potential, 5) +$34MN of incremental Nerve Tape contribution is net of Axoguard Connector + Nerve Cap, and 6) Prostate Open-Label study data was better than prior pilot + single-site studies setting initial contribution into next year. We raise top-line growth outlook for 2027 to 24% (prior 21%) which supports our new, Street high $65 PT (from $58).

$AXGN Q3 revenue was 75.8 million dollars, up 26.2%, and adjusted EPS was 0.21 dollars, up from 0.12 dollars a year ago. Gross margin slipped to 74.8% from 76.6% though. Full year revenue guidance went to at least 290 million dollars. Only 7 million dollars of that is BioCircuit, organic guidance is at least 283 million dollars, so the raise is not just the acquisition that closed Oct. 1. Cash and investments jumped to 350.1 million dollars from 113.4 million dollars in June, but that was mostly the 225 million dollar offering that funded BioCircuit, not operations.

$AXGN reported earnings before the open today. EPS beat estimates: $0.21 vs. $0.13 expected, according to Stock Meadow. What do you think?

My old friend $AXGN back to life. Amazing how time plays a factor in some of these names. Of course sometimes it is a detriment...

$AXGN Does Axogen's $283M organic guide, implying a flat fourth quarter near $76M, leave room for another raise? 🏢 Axogen, which sells nerve-repair grafts and devices to surgeons, posted third-quarter 2026 revenue of $75.8M, up 26.2% from $60.1M, and lifted its 2026 organic revenue floor to $283M, or 26% growth, from at least 24% before 🏦 Axogen has no debt and held $350.1M of cash, restricted cash and investments at September 30, before $200M went to BioCircuit, after selling 10.2M new shares for $358.3M this year; nine-month free cash flow was $18.9M against negative $5.9M a year earlier, and the $37.46 close at 16:00 ET on October 27, 2026 values its 59.7M shares near $2.24B 📅 Next: Axogen hosts a prostate clinical outcomes webcast on November 9, 2026 at 9:00 a.m., ahead of Prostate market development planned for 2027 Source: GlobeNewswire release + SEC 8-K, Oct 28

$AXGN Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $0.21 up 75.00% YoY • Reported revenue of $75.83M up 26.22% YoY • Axogen expects 2026 revenue of at least $290M, at least 29% growth, including at least $7M from BioCircuit; Axogen continues to expect gross margin of at least 73% and positive free cash flow.

$AXGN reports earnings tomorrow before the open. I used Stock Meadow’s earnings dashboard to review its history: AXGN has beaten EPS estimates in 4 of its last 8 reports. Analysts expect EPS of $0.13. What are you watching for?

$AXGN AxoGen closed its BioCircuit acquisition Thursday. NerveTape, which the company calls the first FDA-cleared device for sutureless peripheral nerve repair, is expected to add about 6 million of Q4 revenue and 34 million in 2027. That 2027 number sits outside AxoGen's guidance. On the at-least-24% growth guide off 225.2 million in 2025 revenue, 34 million is roughly 12% of the guided 2026 base. One tuck-in, a double-digit share of next year's sales. The Street is split around the close. Truist cut its target to $53 from $60 on Thursday but kept a Buy. Morgan Stanley downgraded to Hold two days earlier. Raymond James raised its target to $53 six days before that. The tape has fallen five straight days, down 13.8%, closing Friday at 37.39. And Friday saw 9,058 call options trade versus a 322 average.

$AXGN The market is a discounting mechanism. Perhaps the results for their prostatectomy nerve repair trial are not going to be positive. Hope that’s not the case.